Markets

The Quiet Rotation in White Coats

Healthcare absorbed today’s selloff better than technology. The opportunity is not a sector slogan—it is a choice among toll roads, hospitals and pipelines.

There are days when leadership announces itself with a breakout. July 29 offered something quieter: healthcare simply absorbed the punch better.

The S&P 500 fell 1.5% and technology lost 2.4%, while healthcare declined 0.7%. Over the past year, Yahoo Finance sector data showed healthcare up 30.6%, comfortably ahead of technology’s 20.1%. Technology still held a narrow year-to-date advantage—12.2% versus 11.2%—so this is not a clean regime change. It is an increasingly visible rotation toward businesses whose revenues are tied to prescriptions, procedures and patient flow rather than the next incremental dollar of AI capital expenditure.

McKesson: the toll road behind the medicine cabinet

McKesson is not the glamorous part of healthcare, which is precisely its appeal. It sits between drug manufacturers, pharmacies and providers, collecting economics from rising specialty-drug volumes and the expanding oncology ecosystem. The company entered fiscal 2027 guiding adjusted earnings of $43.80 to $44.60 per share, up from $39.11 in fiscal 2026, with expected revenue growth of 5% to 9% and free cash flow of $4.5 billion to $4.9 billion.

At $888.56 after today’s close, MCK was nearly flat on a difficult tape and remained up 8.5% for the year. Distribution margins are thin and policy pressure is real, but the model turns scale, working capital and specialty volume into durable cash generation. It is the kind of compounder that becomes more attractive when the market stops rewarding distant promises.

Hospitals: same demand, different execution

HCA and Tenet show why “buy healthcare” is too simplistic. HCA recently lowered its annual profit forecast as uncompensated care increased. Admissions rose, but surgical volumes softened, and the shares fell 2.4% today. HCA remains a formidable operator with dense local networks, but Medicaid coverage, labor costs and payer mix can quickly turn a volume story into a margin story.

Tenet has offered the cleaner operating surprise. It reported a strong second quarter and raised its 2026 outlook, helped by its ambulatory surgery platform and hospital execution. THC has gained about 29.6% year to date even after falling 1.9% today. The lesson is not that one hospital operator is permanently superior; it is that the market is now rewarding visible throughput and cash conversion, not sector labels.

AstraZeneca and Lilly: growth with different price tags

AstraZeneca reported first-half revenue growth of 6% at constant exchange rates and core earnings-per-share growth of 11%, reaffirming its outlook and its ambition to reach $80 billion of revenue by 2030. The stock rose 0.5% today to $173.30 and was up roughly 9.8% this year. Oncology, rare disease and respiratory medicines give AZN a portfolio rather than a single-product narrative.

Eli Lilly offers the opposite kind of comfort: extraordinary growth paired with extraordinary expectations. The stock closed at $1,210.02, down 0.9% for the session but up about 13% year to date. Its obesity and diabetes franchises have reshaped the company and the industry. Yet manufacturing execution, trial data, payer access and valuation leave less room for ordinary outcomes. Lilly’s next report on August 5 will test whether demand can keep outrunning an already ambitious earnings curve.

Rotation is not abandonment

This rotation does not require a collapse in technology. It only requires investors to ask whether the next dollar is better paid for in a cloud server or a healthcare cash flow that arrives regardless of the market’s mood. Healthcare has demographic demand, product innovation and businesses with recurring utilization. It also has policy risk, reimbursement fights, patent cliffs and labor inflation.

The favorable setup is therefore selective. McKesson’s specialty platform, Tenet’s ambulatory execution, AstraZeneca’s diversified pipeline, HCA’s network density and Lilly’s category leadership are five different ways to own the same broad idea: when multiples wobble, earnings connected to human necessity can become a portfolio’s shock absorber.

Sources

Author positions: The author holds long positions in MCK, HCA, THC, AZN and LLY. Compensation: Neither Aria Vantage nor the author received compensation from any issuer or third party in connection with this article. This is general market commentary for informational and educational purposes, not individualized investment advice or a recommendation. Prices and estimates are as of the July 29, 2026 close unless otherwise stated. Read the full disclosures.